SOURCE-LINKED STUDY SUMMARY
Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study.
Abstract summarizedQuality not appraised
- What was studied
- A prospective observational study tracked heart structure and function after tirzepatide was started in routine care.
- Who / model studied
- Fifty adults at one centre had obesity-related heart failure with preserved pumping function. Median follow-up was 5.8 months; changes were compared with their own starting measurements.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The two primary measures improved: left-ventricular mass fell 12.4 grams and an ultrasound estimate of heart-filling pressure fell 1.45 units. Other outcomes included walking 43 metres farther in six minutes and improved symptom class in 60%. These were before-and-after associations.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.ijcard.2026.134773